Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Inks Pact With EU For Coronavirus Vaccine

Deal Is For At Least 300 Million Doses

Executive Summary

The agreement will give all EU member states the option to access the drug major's investigational COVID-19 vaccine dubbed AZD1222 "in an equitable manner at no profit during the pandemic."

You may also be interested in...



Coronavirus Notebook: UK Ups Vaccine Efforts & Calls For More Candidate Therapies

The UK has been stepping up its COVID-19 activity in recent days, ordering more vaccines, encouraging more volunteers to join clinical trials, and expanding its RECOVERY platform for potential new coronavirus therapies. But the government's sudden decision to replace Public Health England with a new institute has raised some concerns within the biopharma industry.

Coronavirus Update: J&J’s Single Dose Stands Out From COVID Vaccine Crowd

J&J is a few months behind companies like Moderna, Pfizer and AstraZeneca in the race to develop a vaccine, but a safe and effective single dose immunization would be a game changer.

EU Takes Over COVID-19 Vaccine Negotiations, But Lags Behind US

A quartet of EU countries started vaccine procurement talks with AstraZeneca, but are now allowing the European Commission to take over negotiations.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel